With the exception of ALK (anaplastic lymphoma kinase) positive anaplastic large cell lymphoma, PTCL exhibits an aggressive course and patients have a poor outcome after conventional chemotherapy[4-7] with a median overall survival (OS) of 9 to 42 months[8-10]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.